Cerus Settles Class Action, Derivative Lawsuits
Biopharmaceutical company Cerus Corp. has settled a federal securities class action lawsuit and a derivative shareholder suit that alleged the company concealed risks about one of its products from investors....To view the full article, register now.
Already a subscriber? Click here to view full article